Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Intrust Bank NA

Intrust Bank NA raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 31.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,872 shares of the medical equipment provider’s stock after purchasing an additional 687 shares during the quarter. Intrust Bank NA’s holdings in Zimmer Biomet were worth $303,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in shares of Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after acquiring an additional 125,852 shares in the last quarter. Van ECK Associates Corp increased its stake in Zimmer Biomet by 5.9% in the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock valued at $417,814,000 after buying an additional 218,688 shares during the period. Norges Bank purchased a new stake in shares of Zimmer Biomet during the fourth quarter worth $216,223,000. Hotchkis & Wiley Capital Management LLC lifted its holdings in shares of Zimmer Biomet by 49.1% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock valued at $189,161,000 after buying an additional 577,320 shares during the last quarter. Finally, Equity Investment Corp lifted its stake in Zimmer Biomet by 57.2% in the fourth quarter. Equity Investment Corp now owns 1,021,062 shares of the medical equipment provider’s stock valued at $107,855,000 after acquiring an additional 371,653 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.95% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have weighed in on ZBH shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Stifel Nicolaus raised their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. JMP Securities restated a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Finally, Barclays dropped their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Stock Up 0.1 %

Shares of NYSE:ZBH opened at $112.21 on Monday. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $131.61. The stock has a market cap of $22.34 billion, a price-to-earnings ratio of 25.22, a P/E/G ratio of 1.95 and a beta of 1.04. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The company has a 50 day moving average of $107.18 and a 200-day moving average of $107.04.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the company earned $2.20 EPS. On average, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.86%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.